These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 3304906)

  • 1. Effects of intranasal insulin in non-obese type II diabetics.
    Frauman AG; Jerums G; Louis WJ
    Diabetes Res Clin Pract; 1987; 3(4):197-202. PubMed ID: 3304906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meal-time intranasal insulin delivery in type 2 diabetes.
    Bruce DG; Chisholm DJ; Storlien LH; Borkman M; Kraegen EW
    Diabet Med; 1991 May; 8(4):366-70. PubMed ID: 1830259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal insulin: the effects of three dose regimens on postprandial glycaemic profiles in type II diabetic subjects.
    Coates PA; Ismail IS; Luzio SD; Griffiths I; Ollerton RL; Vølund A; Owens DR
    Diabet Med; 1995 Mar; 12(3):235-9. PubMed ID: 7758260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
    Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
    Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.
    Nauck MA; Wollschläger D; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Willms B
    Diabetologia; 1996 Dec; 39(12):1546-53. PubMed ID: 8960841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.
    Owens DR
    Diabet Med; 1998; 15 Suppl 4():S28-36. PubMed ID: 9868989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous insulin simulates early insulin peak and reduces post-prandial hyperglycaemia/hyperinsulinaemia in type 2 (non-insulin-dependent) diabetes mellitus.
    Luzio SD; Owens DR; Vora J; Dolben J; Smith H
    Diabetes Res; 1991 Feb; 16(2):63-7. PubMed ID: 1817807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fasting plus prandial insulin supplements improve insulin secretory ability in NIDDM subjects.
    Kawamori R; Bando K; Yamasaki Y; Kubota M; Watarai T; Iwama N; Shichiri M; Kamada T
    Diabetes Care; 1989; 12(10):680-5. PubMed ID: 2515048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fasting and postprandial plasma glucose and peripheral insulin levels in insulin-dependent diabetes mellitus and non-insulin-dependent diabetes mellitus subjects during continuous intraperitoneal versus subcutaneous insulin delivery.
    Hermans MP; van Ypersele de Strihou M; Ketelslegers JM; Squifflet JP; Buysschaert M
    Transplant Proc; 1995 Dec; 27(6):3329-30. PubMed ID: 8539974
    [No Abstract]   [Full Text] [Related]  

  • 10. Cholinergic blockade with pirenzepine induces dose-related reduction in glucose and insulin responses to a mixed meal in normal subjects and non-insulin dependent diabetics.
    Bevan JS; Ara J; Page MD; Scanlon MF; Peters JR
    Clin Endocrinol (Oxf); 1991 Jul; 35(1):85-91. PubMed ID: 1889143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Could intranasal insulin be useful in the treatment of non-insulin-dependent diabetes mellitus?
    Kimmerle R; Griffing G; McCall A; Ruderman NB; Stoltz E; Melby JC
    Diabetes Res Clin Pract; 1991 Aug; 13(1-2):69-75. PubMed ID: 1773716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of acarbose on postprandial increase in blood glucose. Additive acute effect of once daily administration in insulin treated diabetes].
    Ledermann H; Höxter G
    Fortschr Med; 1994 Nov; 112(32):467-70. PubMed ID: 7821886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a combination of bedtime intermediate-acting insulin and glibenclamide in type 2 (non-insulin-dependent) diabetic patients with secondary failure to respond to oral hypoglycaemic agents.
    Krempf M; Godeau T; Ranganathan S; Blanchard P; Ritz P; Charbonnel B
    Eur J Clin Pharmacol; 1992; 42(3):281-6. PubMed ID: 1577046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal aerosolized insulin. Mixed-meal studies and long-term use in type I diabetes.
    Salzman R; Manson JE; Griffing GT; Kimmerle R; Ruderman N; McCall A; Stoltz EI; Mullin C; Small D; Armstrong J
    N Engl J Med; 1985 Apr; 312(17):1078-84. PubMed ID: 3885035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of intranasal insulin administered to patients with type 1 diabetes: a preliminary study.
    Leary AC; Stote RM; Cussen K; O'Brien J; Leary WP; Buckley B
    Diabetes Technol Ther; 2006 Feb; 8(1):81-8. PubMed ID: 16472054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A practical guide to basal and prandial insulin therapy.
    Holman RR; Turner RC
    Diabet Med; 1985 Jan; 2(1):45-53. PubMed ID: 2951066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus.
    Jones IR; Owens DR; Luzio S; Williams S; Hayes TM
    Diabetologia; 1989 Sep; 32(9):668-77. PubMed ID: 2676668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
    Kikuchi M
    Diabet Med; 1996 Sep; 13(9 Suppl 6):S151-5. PubMed ID: 8894500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM.
    Kolterman OG; Schwartz S; Corder C; Levy B; Klaff L; Peterson J; Gottlieb A
    Diabetologia; 1996 Apr; 39(4):492-9. PubMed ID: 8778001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes.
    Kipnes M; Dandona P; Tripathy D; Still JG; Kosutic G
    Diabetes Care; 2003 Feb; 26(2):421-6. PubMed ID: 12547873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.